Baseline cancer demographics
| Cases (n = 101) | Controls (n = 201) | P value | |
|---|---|---|---|
| Single agent vs. combined | |||
| Combination | 28 (28) | 14 (7) | < 0.001 |
| Monotherapy | 73 (72) | 177 (93) | < 0.001 |
| Combined ICI | |||
| Ipilimumab (anti-CTLA4) + nivolumab (anti-PD1) | 24 (24) | 13 (6) | < 0.001 |
| Ipilimumab (anti-CTLA4) + pembrolizumab (anti-PD1) | 1 (1) | 0 | 0.33 |
| Tremelimumab (anti-CTLA4) + avelumab (anti-PD1) | 1 (1) | 0 | 0.33 |
| Tremelimumab (anti-CTLA4) + durvalumab (anti-PD1) | 2 (2) | 1 (0) | 0.26 |
| Monotherapy ICIa | |||
| Pembrolizumab (anti-PD1) | 35 (35) | 62 (31) | 0.50 |
| Nivolumab (anti-PD1) | 25 (25) | 85 (42) | 0.003 |
| Ipilimumab (anti-CTLA4) | 6 (6) | 28 (14) | 0.04 |
| Tremelimumab (anti-CTLA4) | 1 (1) | 0 | 0.33 |
| Atezolizumab (anti-PDL1) | 6 (6) | 2 (1) | 0.02 |
| Avelumab (anti-PDL1) | 0 | 0 | 1.00 |
| Durvalumab (anti-PDL1) | 0 | 0 | 1.00 |
| Overall types of ICI | |||
| Any anti-PD1 | 85 (84) | 160 (80) | 0.34 |
| Any anti-CTLA4 | 35 (35) | 42 (21) | 0.01 |
| Any anti-PDL1 | 9 (9) | 3 (1) | 0.003 |
| Days of follow-up [IQR] | 175 [89,363] | 290 [139,543] | < 0.001 |
| Other immune side effects during treatmentb | |||
| No other immune side effects | 51 (50) | 86 (43) | 0.20 |
| Hypophysitis/pituitary/adrenal | 6 (6) | 14 (7) | 0.74 |
| Pneumonitis | 30 (30) | 24 (12) | < 0.001 |
| Hepatitis | 8 (8) | 11 (5) | 0.41 |
| Colitis | 9 (9) | 27 (13) | 0.25 |
| Dermatitis | 6 (6) | 5 (2) | 0.19 |
| Neurological | 11 (11) | 4 (2) | 0.001 |
| Gastritis | 3 (3) | 5 (2) | 1.00 |
Values are n (%) or mean ± SD. All cases with ICI-associated myocarditis had ICI permanently discontinued. aIf most recent ICI therapy was monotherapy. bMore than one immune side effect may occur. Anti-CTLA4 anti-cytotoxic T-lymphocyte-associated protein 4, anti-PD1 anti-programmed cell death protein 1, anti-PDL1 anti-programmed death-ligand 1, ICI immune checkpoint inhibitors